Company Overview of Sun BioPharma, Inc.
Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing disruptive therapeutics for severe unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase I clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts at The Ohio State University; the Fred Hutchinson Cancer Center; Translational Genomics; AZ; Cedars Sinai Medical Center; the University of Minnesota; the University of Miami; the Austin Health Cancer Trials Centre; the Box Hill Hospital; and the Ashford Cance...
712 Vista Boulevard
Waconia, MN 55387
Key Executives for Sun BioPharma, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $78.0K
Co-founder and Executive Chairman
Total Annual Compensation: $90.0K
Chief Financial Officer, Vice President of Finance and Secretary
Total Annual Compensation: $50.0K
Compensation as of Fiscal Year 2015.
Sun BioPharma, Inc. Key Developments
Sun BioPharma, Inc. Receives DSMB Approval to Start Fourth Patient Cohort in the Dose Escalation Phase 1 Study of SBP-101 for Pancreatic Cancer
Oct 6 16
Sun BioPharma, Inc. announced that the Data Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the clinical trial, has completed its safety review of the data from the dosing of the third cohort of patients. As a result of this positive review by the DSMB, the company has initiated the fourth patient cohort in the dose escalation phase of the study. The company currently expects to begin dosing patients in the fourth cohort as early as October 10, 2016, which is approximately 60 days after the third patient cohort commenced dosing. The company is currently conducting a clinical trial of SBP-101 in patients with previously treated locally advanced or metastatic pancreatic cancer. This is a Phase 1, first-in-human study with a dose-escalation phase and an expansion phase at the anticipated recommended treatment dose. This study is being conducted at clinical sites in both Australia and the United States including Mayo Clinic Scottsdale and HonorHealth in Scottsdale, AZ, the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia.
Sun Biopharma Announces Completion of the Second Patient Cohort and Starts Recruitment of Third Cohort Patients in the Dose Escalation Phase 1 Study of SBP101 for Pancreatic Cancer
Aug 15 16
Sun BioPharma, Inc. reported additional progress in the Phase 1 Study of the Company’s candidate SBP101 for pancreatic cancer. The Study’s Data Safety Monitoring Board (DSMB) has completed its independent safety review of the data from the dosing of the second cohort of patients. As a result of this review, the Company has implemented progression to the third patient cohort in the dose escalation phase of the study. The Data Safety Monitoring Board is chaired by James Abbruzzese, MD, Professor of Medicine, member of Duke Cancer Institute and Chief, Division of Medical Oncology at Duke University School of Medicine, who is one of the foremost leaders in the clinical study and treatment of pancreatic cancer and co-chaired by Dr. David Goldstein, Conjoint Professor and a Senior Staff Specialist in the Department of Medical Oncology at Prince of Wales Hospital in Sydney, Australia who has extensively studied the influence of host cells on tumor progression in pancreatic cancer. Three of the Company’s study sites are in Australia: The Ashford Cancer Centre in Adelaide, the Olivia Newton-John Cancer & Wellness Centre and Box Hill Hospital at Monash University, both in Melbourne, and two study sites are in the United States: Mayo Clinic in Scottsdale, AZ and Honor Health in Scottsdale, AZ.
Sun BioPharma, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended of June 30, 2016
Aug 11 16
Sun BioPharma, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended of June 30, 2016. For the quarter, the company reported operating loss of $949,000 compared to $1,193,000 a year ago. Loss before income tax benefit was $1,068,000 compared to $1,253,000 a year ago. Net loss was $978,000 compared to $1,215,000 a year ago. Basic and diluted net loss per share was $0.03 compared to $0.18 a year ago. Net cash used in operating activities was $542,000 compared to $907,000 a year ago. The net cash used in each of these periods primarily reflects the net loss for these periods, and was partially offset by the effects of changes in operating assets and liabilities and, in the three months ended March 31, 2015, by non-cash charges recorded for share-based compensation.
For the six months, the company reported operating loss of $1,924,000 compared to $3,384,000 a year ago. Loss before income tax benefit was $2,005,000 compared to $3,502,000 a year ago. Net loss was $1,799,000 compared to $3,407,000 a year ago. Basic and diluted net loss per share was $0.06 compared to $0.55 a year ago. Net cash used in operating activities was $631,000 compared to $2,141,000 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 10, 2016